-- 
Israeli Stocks: Avner, Bioline, Delek, Exalenz, Mellanox

-- B y   S h a r o n   W r o b e l
-- 
2011-07-24T15:00:25Z

-- http://www.bloomberg.com/news/2011-07-24/israeli-stocks-avner-bioline-delek-exalenz-mellanox.html
Israel ’s TA-25 Index climbed to the
the highest in two weeks, increasing 0.3 percent to 1,266.73 at
the 4:30 p.m. close in  Tel Aviv . Investors traded about 874.5
million shekels ($257 million) in shares and convertible
securities.  The following stocks rose or fell today. Symbols are in
parentheses.  Avner Oil Exploration-LP (AVNRL IT) rose to the highest
level since May 22, advancing 1.5 percent to 2.181 shekels. The
oil and gas explorer and Delek Drilling-LP (DEDRL IT) said a new
layer of gas was discovered at the Tamar gas field’s number 3
site, which may raise the reserve estimate to as much as 9.14
trillion cubic feet. Delek Drilling increased 1.8 percent to
12.28 shekels.  Bioline RX Ltd. (BLRX)   advanced 6.5 percent to 1.764
shekels, the most since July 3. The pharmaceutical development
company said it will tomorrow start trading American Depositary
Receipts on the Nasdaq Stock Market.  Exalenz Bioscience Ltd. (EXEN)   jumped 8.4 percent to
0.887 shekel, the biggest gain since June 2010. The developer of
breath-testing systems said its first trial of BreathID to
diagnose  liver cancer  was successful and it now plans to conduct
an advanced clinical trial of the product.  Israel Land Development Co. (ILDC IT) advanced the most in
more than a month, increasing 5.9 percent to 31.85 shekels.
Psagot Investment House Ltd. started coverage of the  investment
company  with a “buy” recommendation and a price estimate of
51.4 shekels.  Mellanox Technologies Ltd. (MLNX)   surged 9 percent to
113.70 shekels, the highest since it began trading in 2007. The
Israeli maker of data-center adapters and software reported
second-quarter profit that beat analysts’ estimates.  To contact the reporter on this story:
{Sharon Wrobel} in Tel Aviv at 
 swrobel4@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  